Medications for Cardiovascular Diseases

48 results

  • Atorvastatin calcium (atorvastatin calcium)

    (Atorvastatin Calcium)
    Northwind Pharmaceuticals
    Usage: Atorvastatin calcium is indicated for reducing cardiovascular disease risk in adults with multiple risk factors, managing hyperlipidemia, and as an adjunct to diet for lowering elevated cholesterol and triglyceride levels in various conditions, including familial hypercholesterolemia. It should not be used for certain lipoprotein abnormalities.

  • Atorvastatin calcium (atorvastatin calcium)

    (Atorvastatin Calcium)
    NuCare Pharmaceuticals,Inc.
    Usage: Atorvastatin calcium is indicated for lowering cholesterol and triglycerides in patients with hyperlipidemia and for reducing cardiovascular risks in adults with or without coronary heart disease. It serves as an adjunct to diet for various dyslipidemias and in children with heterozygous familial hypercholesterolemia, when necessary.

  • Atorvastatin calcium (atorvastatin calcium)

    (Atorvastatin Calcium)
    NuCare Pharmaceuticals,Inc.
    Usage: Atorvastatin calcium is indicated for reducing cardiovascular disease risks in adults with multiple risk factors and hyperlipidemia. It serves as an adjunct to diet for lowering cholesterol and triglyceride levels in patients with various dyslipidemias, including familial hypercholesterolemia and mixed dyslipidemia.

  • Ezallor sprinkle (rosuvastatin)

    (ROSUVASTATIN)
    Sun Pharmaceutical Industries, Inc.
    Usage: EZALLOR SPRINKLE is indicated to reduce the risk of major adverse cardiovascular events in at-risk adults, lower LDL cholesterol in various hyperlipidemia types, and treat primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It can be used alone or with other LDL-lowering therapies for patients with familial hypercholesterolemia.

  • Glyxambi

    (empagliflozin and linagliptin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Usage: GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

  • Jardiance

    (Empagliflozin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Usage: JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.

  • Jardiance (empagliflozin)

    (Empagliflozin)
    Aphena Pharma Solutions - Tennessee, LLC
    Usage: JARDIANCE is indicated for improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, and for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Not recommended for type 1 diabetes or diabetic ketoacidosis.

  • Liraglutide (liraglutide)

    (liraglutide)
    Teva Pharmaceuticals USA, Inc.
    Usage: Liraglutide is indicated for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes, and reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not for use in type 1 diabetes patients.

  • Liraglutide (liraglutide)

    (liraglutide)
    A-S Medication Solutions
    Usage: Liraglutide is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients (ages 10+) with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Not for type 1 diabetes use.

  • Praluent

    (alirocumab)
    Regeneron Pharmaceuticals, Inc.
    Usage: PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.